IL1B and triple-A syndrome: Both IL-1α and IL-1β played a key role in KD disease, and the use of IL-1R blockers that inhibited both pathways might be a therapeutic target not only for KD coronary arteritis but also for other systemic aneurysms, including AAA (Lee et al., 2015; Wakita et al., 2016).